The TNBC subtype accounts for 20% of BC cases, and is characterized by ER-/PR-/HER2-, high expression of proliferation-related genes, an aggressive phenotype, and early relapse [3,5,8]. This evidence concerns the gene ERBB2 and breast cancer.